Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year High at $3.05

Cardiol Therapeutics Inc. (TSE:CRDL) hit a new 52-week high during trading on Thursday . The company traded as high as C$3.05 and last traded at C$3.00, with a volume of 333738 shares traded. The stock had previously closed at C$2.75.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Cardiol Therapeutics in a research report on Monday, April 22nd.

Cardiol Therapeutics Stock Performance

The company has a current ratio of 5.29, a quick ratio of 6.84 and a debt-to-equity ratio of 0.52. The company has a market cap of C$197.28 million, a P/E ratio of -6.40 and a beta of 0.75. The company has a 50 day moving average price of C$2.41 and a 200-day moving average price of C$1.73.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.